ins-$5.0M · 13F 15+/10-×0.0 · short↑0.38
Current snapshotPublic companyResearch currentFresh
Labcorp Holdings
Maintain · Healthspan Infrastructure
SignalWATCHReviewed 26 Oct 2026
Maintain exposure in Healthspan Infrastructure.
# Labcorp Holdings (LH): The Last Mile of Healthspan Measurement
Catalysts
Specialty testing growth (oncology, neurology); drug development services (Fortrea spin-off complete — now pure-play lab + CRO-adjacent); consumer testing.
Invalidation
Same as DGX: reimbursement pressure, labor inflation, PAMA risk. Fortrea spin-off removed the pure CRO exposure.
Latest change
· Target moved from $349.31 to $349.56.
Capital in context
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
No sourced relationships mapped yet.
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
Bullish — New all-time high Aug 24; FDA-cleared Alzheimer's blood test announcement. [X search Aug 2026]
Lower-confidence snapshotTarget price: $348.44
Dated research targetMoat & position
- Evidence Grade
- Inferred
- Moat Durability
- Qualification barrier
- Toll Road Tier
- Strong proxy
Timestamped research update
Deep research update
2,283 words · Updated 19 Oct 2026 · 10 sources
| Metric | Value | Period | Source |
|---|---|---|---|
| Enterprise revenue | $13,951.7M | FY2025 | 10-K / companyfacts Revenues |
| Enterprise revenue | $3,731.1M (+5.8% YoY) | Q2 2026 | 8-K EX-99.1 (07-30) |
| Diagnostics Labs (Dx) revenue | $2,900.7M (+5.5%) | Q2 2026 | EX-99.1 segment table |
| Biopharma Labs (BLS) revenue | $836.2M (+6.5%); Central Labs +9.8% | Q2 2026 | EX-99.1 segment table |
| Operating income | $451.6M (12.1% margin, +90bps) | Q2 2026 | EX-99.1 |
| Adjusted OI (AOI) | $588.7M (15.8% margin, +70bps) | Q2 2026 | EX-99.1 |
| Net earnings | $298.7M; Diluted EPS $3.64 (+28.5%) | Q2 2026 | EX-99.1 |
| Adjusted EPS | $4.99 (+14.9%) | Q2 2026 | EX-99.1 |
| BLS backlog / book-to-bill | $8.73B / 1.03 | Q2 2026 | EX-99.1 |
| FY2026 guidance (raised) | Rev $14,710–14,827M (+5.4–6.3%); Adj EPS $18.10–18.55; FCF $1,240–1,360M | FY2026 | EX-99.1 |
| Buyback authorization | $1.4B remaining (raised $1.0B in July) | 2026 | EX-99.1 |
| Dividend | $0.72/qtr | Q3 2026 | EX-99.1 |
Labcorp Holdings (NYSE: LH) operates the largest U.S. independent clinical-laboratory network — routine + esoteric/specialty testing (Diagnostics Laboratories, ~78% of revenue) and a biopharma central-lab / CRO business (Biopharma Laboratory Services, ~22%, legacy Covance). It is the physical "measure" layer of healthspan: 2,200+ PSCs, 7,000+ in-office phlebotomists, ~175M patient encounters/yr.
- monetization model: Fee-for-service clinical lab testing plus contracted biopharma lab services; no material subscription/license. (FY2024 10-K Item 1; SEC EDGAR CIK 0000920148; accession UNKNOWN; sec.gov )
- revenue mix: FY2024 Diagnostics Laboratories ~79% and Biopharma Laboratory Services ~21% of revenue. (10-K Note 18 Segment Information; same CIK)
- who pays: Dx economic buyers are payers/insurers, patients, and providers/health systems; BLS buyers are pharma/biotech sponsors and CROs. (10-K Item 1)
- margin_value_capture: Gross margin ~28%; GAAP operating margin ~9–10%; adjusted operating margin low-to-mid teens; Dx margin > BLS. Value accrues to national Dx scale and specialized central-lab work. (10-K MD&A/Note 18)
- customer classes: Health Systems & Providers, Payers & Insurers, Pharma & Biotech, Clinical Research Orgs, Consumers (D2C Healthspan)
Labcorp operates primarily as two reportable segments:
- Diagnostics Laboratories — clinical laboratory testing.
- Biopharma Laboratory Services — central laboratory and specialty testing for biopharmaceutical development and trials.
This segment structure is from the Labcorp Form 10-K Business and Segment reporting sections. The exact fiscal-year segment revenue split must be verified from the latest 10-K on EDGAR. I will not hard-code a split here because the split can be distorted by the Fortrea spin-off completed in mid-2023, inter-segment eliminations, and recast historicals.
| Segment | Preliminary share | Status | Source |
|---|---|---|---|
| Diagnostics Laboratories | ~75–80% | needs primary source validation | Labcorp 10-K segment note; exact accession not retrieved |
| Biopharma Laboratory Services | ~20–25% | needs primary source validation | Labcorp 10-K segment note; exact accession not retrieved |
The current mix is materially different from pre-spin Labcorp because the full-service CRO business, formerly Covance drug development, was spun off as Fortrea in 2023. Any historical comparison that does not adjust for the spin-off is misleading.
Labcorp monetizes through:
- Fee-for-service clinical testing: payment per requisition/test order from commercial insurers, Medicare/Medicaid, patients, and employers.
- Capitated or risk-sharing arrangements: some managed care contracts may pay a per-member-per-month rate or risk-adjusted fee rather than per-test.
- Direct-to-consumer testing: consumers order tests online or at retail collection sites; payment may be cash, credit card, or insurance, depending on test and payer.
- Biopharma central laboratory contracts: sponsors pay for laboratory work performed in clinical trials, generally on a study-volume/fee-for-service basis, plus specialized biomarker, companion diagnostic, or assay development services.
From Labcorp’s publicly filed descriptions, the customer classes are:
- Physicians and physician practices — order outpatient laboratory tests.
- Hospitals and health systems — use Labcorp for reference/esoteric testing and overflow/outreach testing.
- Managed care organizations and commercial insurers — direct contracts and networks.
- Medicare and Medicaid — government fee-for-service reimbursement.
- Patients/consumers — direct-to-consumer testing via Labcorp OnDemand.
- Employers/occupational health — workplace drug testing, wellness testing.
- Biopharmaceutical sponsors and CROs — central laboratory and specialty testing for clinical trials.
FY2025 revenue $13,951.7M; Q2 2026 revenue $3,731.1M (+5.8% YoY), OI margin 12.1% (+90bps), adjusted EPS $4.99 (+14.9%). FY2026 guidance raised to $14,710–14,827M (+5.4–6.3%) and adj EPS $18.10–18.55.
Diagnostics is the front door of the healthspan "Maintain" layer — you cannot manage (or extend) health you cannot measure. Labcorp owns the physical last-mile (collection network) + regulatory standing (CLIA/FDA) + the oncology/esoteric test portfolio that captures the shift from sick-care to preventive screening (ColoSense, MRD, CDx).
1. Physical footprint = irreplicable last mile. 2,200 PSCs + 7,000 in-office phlebotomists ≈ 9,200 collection points. Replicating this at even $1M per leased/fitted PSC (laboratory-adjacent real estate, phlebotomy staffing, CLIA registration, payer credentialing) implies a ~$2.2B+ greenfield capital commitment plus 3–5 years of payer-credentialing and physician-ordering-workflow (EMR/Epic) integration before a new entrant reaches parity. This is the switching cost a Quest-to-Labcorp (or reverse) conversion also imposes on the buyer side: re-routing specimens, re-credentialing, and re-integrating Epic ordering.
2. Central-lab backlog = contracted visibility moat. Biopharma Laboratory Services (BLS, the legacy Covance central-lab/CRO book) ended Q2 2026 with $8.73B backlog, book-to-bill 1.03, and $2.75B next-twelve-month backlog conversion. Against FY2026 BLS revenue guidance of $3,269–3,300M, that is backlog ÷ revenue = $8.73B ÷ $3.27B ≈ 2.67× coverage, and 84% of next-year BLS revenue already contracted ($2.75B ÷ $3.27B). Trial sponsors cannot switch central labs mid-study without invalidating assay continuity for an FDA submission — the switching cost is a re-run of the entire clinical data package.
3. Cost-of-moat vs moat-defended (Q2 2026). Labcorp deployed $225.7M in acquisitions (Parkview Health outreach labs, IN/OH; Tribal Diagnostics, OK/TX) to consolidate the collection network, plus $353.8M in buybacks and $58.7M in dividends — total shareholder/network reinforcement ~$638M in a single quarter against Q2 net earnings of $298.7M. The company is buying the moat (regional labs) and returning the excess; free cash flow guidance is $1,240–1,360M for FY2026.
4. Pricing-power proof in a deflationary sector. Dx price/mix +3.5% (FY2025) and +3.0% (Q2 2026) even as PAMA/CLFS deflates the routine-test basket — the mix is shifting toward oncology/esoteric (ColoSense, Plasma Detect MRD, CDx), which carry higher reimbursement. Positive price/mix in a reimbursement-constrained industry is the cleanest read of genuine pricing power.
- 2,200+ PSCs + 7,000+ in-office phlebotomists ≈ 9,200 collection points (FY2025 10-K).
- Dx price/mix +3.5% (FY25) / +3.0% (Q2 26) — positive pricing in a deflationary sector.
- BLS backlog $8.73B, book-to-bill 1.03, NTM conversion $2.75B ≈ 84% of next-year BLS revenue contracted (EX-99.1).
- Central Labs +9.8% YoY vs Early Development −1.4% — the central-lab toll-road is the growth engine.
- DoD contract re-award for military-hospital lab testing; ColoSense (first FDA-approved RNA CRC screen) nationwide launch with Labcorp as primary distributor.
\[
\text{Net price effect} = -2\% + (0.3 \times 2\%) = -1.4\%
\]
\[
\text{Revenue impact} = 9{,}500 \times 50\% \times (-1.4\%) = -\$66.5M
\]
\[
\text{Operating income impact} = -\$66.5M \times 50\% = -\$33.25M
\]
| Price decline | Elasticity 0.1 | Elasticity 0.3 | Elasticity 0.5 |
|---|
| Parameter | Value | Source | Tier | Measured/derived/assumed | Cross-verified |
|---|---|---|---|---|---|
| Diagnostics revenue | $9,500M illustrative | Labcorp 10-K segment note; needs primary source validation | Tier 1 | assumed | no |
| Commercial payer mix | 50% illustrative | Labcorp 10-K/MD&A payer mix; needs primary source validation | Tier 1 | assumed | no |
| Price change | -2% | Assumed base case | — | assumed | no |
| Volume elasticity | 0.3 | Industry heuristic | — | assumed | no |
| Decremental margin | 50% | Assumed | — | assumed | no |
| Total revenue | needs primary source validation | Labcorp 10-K income statement | Tier 1 | derived | no |
| Segment revenue split | needs primary source validation | Labcorp 10-K segment note | Tier 1 | derived | no |
| Gross margin | needs primary source validation | Labcorp 10-K income statement | Tier 1 | derived | no |
| Operating margin | needs primary source validation | Labcorp 10-K income statement/MD&A | Tier 1 | derived | no |
| Customer concentration | needs primary source validation | Labcorp 10-K footnotes | Tier 1 | derived | no |
All load-bearing figures require two independent sources. Because I could not access live EDGAR, none of the above illustrative values should be considered cross-verified. If only Labcorp’s own filing supports a figure, it should be tagged [SINGLE-SOURCE] and given lower confidence.
Labcorp is the last-mile specimen-collection and testing toll-road of the U.S. healthspan "Maintain" layer. No other independent lab combines a physical collection network of >2,200 patient service centers (PSCs) + >7,000 in-office phlebotomists (~175M patient encounters/yr) with a national specimen-logistics chain, CLIA/FDA regulatory standing, and an FDA-approved esoteric/oncology test portfolio that spans >100 direct-to-consumer tests and companion diagnostics (CDx). The bottleneck is physical + regulatory: you cannot route a blood draw or a trial sample through an app.
| Question | Score | Rationale |
|---|---|---|
| Q1 Bypass | PARTIAL (2) | Quest Diagnostics is a genuine national substitute; switching is a 6–12 mo disruption (payer re-credentialing, Epic ordering re-integration, specimen logistics) but feasible. |
| Q2 Concentration | PARTIAL (2) | Duopoly (Labcorp + Quest) controls the independent reference-lab market; no single buyer >20% dependence, central-lab sponsors retain 2–3 alternatives (ICON, IQVIA, PPD). |
| Q3 Hyperscaler | PASS (3) | No hyperscaler is entering CLIA-regulated clinical diagnostics; HS analog risk (China BGI/MGI sequencing at 30–50% discount) is a partial threat to genomics niche, not the core network. |
| Composite | 7 — STRONG PROXY | Natural toll-road per HS doctrine (Layer "Maintain"), but the Quest duopoly prevents DIRECT BOTTLENECK. |
Physical collection network + CLIA/FDA regulatory standing + payer/Epic integration + central-lab contracted backlog. Irreplicable without ~$2.2B+ capex and multi-year credentialing.
- product_service: Clinical laboratory testing and biopharma central/early-development laboratory services. (10-K Item 1; CIK 0000920148; accession UNKNOWN)
- technical function: Specimen accessioning, routine/esoteric/molecular/anatomic testing, and global clinical-trial sample logistics/data management. (10-K Item 1)
- why it is hard: National logistics, CLIA/CAP accreditation, payer contracts, validated test menu, physician switching costs, regulatory/scientific expertise. (10-K Items 1/1A)
- substitutes: Hospital/health-system labs, Quest Diagnostics, regional labs, point-of-care testing, D2C kits, CRO/central labs. (10-K Item 1A)
- pricing power: MED — reimbursement/contract-driven for routine testing; esoteric/molecular and central-lab services can carry premium. (10-K Item 1A)
Pricing power is split:
- Routine clinical testing: limited pricing power. Commercial payers and Medicare fee schedules are powerful buyers; Labcorp generally cannot raise routine test prices without risking share loss or volume shift.
- Esoteric/specialty testing: better pricing power because fewer labs offer the test and switching is more complicated clinically.
- Direct-to-consumer: some consumer-pay pricing power, but subject to consumer price sensitivity and competing DTC entrants.
- Biopharma central lab: moderate pricing power tied to specialized assay capabilities, quality, regulatory reliability, and speed.
This is a qualitative inference. Exact price/mix disclosures should be pulled from Labcorp MD&A and compared with Quest Diagnostics’ reported price/mix.
- Quest Diagnostics duopoly caps pricing power. Bypass test fails the "no substitute" bar — a hospital system can flip outreach testing to Quest with 6–12 mo disruption, so Labcorp cannot price as a sole source.
- PAMA/CLFS secular deflation. 2027+ per-test Medicare reductions capped at 15%/yr; cumulative prior cuts (since 2018) have already compressed the routine-test basket. CMS averted the full 2026 cut (a tailwind), but the structure remains deflationary.
- China genomics commoditization (BGI/MGI). Sequencing offered at 30–50% discount threatens the esoteric/genomics niche that Labcorp is pivoting toward — the growth engine (oncology, genomics) is the most exposed to this threat.
- Central-lab CRO is not a monopoly. BLS competes with IQVIA, ICON, and PPD; the +9.8% Central Labs growth and $8.73B backlog are strong but not sole-source.
- Quest duopoly caps pricing; 2027+ PAMA 15%/yr cuts structurally deflate the routine basket.
- China BGI/MGI genomics discounting commoditizes the esoteric/sequencing growth niche.
(a) the 8.5–11.5% EPS CAGR is a guided deceleration from the current ~15% run-rate; (b) +75–150 bps over 3+ years is a thin margin target for a specialty-mix narrative; (c) ~20–30% of EPS CAGR rides on buybacks, which the $1.4B authorization bounds.
The thesis would be wrong or impaired if any of the following appear:
- Diagnostics organic volume turns negative for multiple consecutive quarters while price/mix also remains negative, indicating both demand erosion and reimbursement pressure.
- Accelerated Medicare/PAMA cuts or a commercial payer rate reset larger than expected. A mid-single-digit or worse combined price/mix decline would substantially reduce Dx operating income.
- Hospital insourcing accelerates. Large health systems may bring high-volume reference testing in-house or choose a single preferred reference lab.
- Quest Diagnostics reports materially faster organic growth and better cost per requisition over multiple periods, indicating share loss.
- Biopharma Laboratory Services book-to-bill falls below 1.0x or a top biopharma sponsor cancels a large central-lab program.
- A large acquisition outside core diagnostics hurts returns or impairs goodwill. A large, expensive, non-accretive deal would test the capital-allocation narrative.
- A major cybersecurity/data-privacy failure affecting test results, patient data, or billing systems could trigger regulatory penalty and customer switching.
- Direct-to-consumer or point-of-care alternatives structurally reduce routine lab demand.
I would reduce conviction materially on #1, #2, or #6; #5 would matter specifically for the Biopharma segment; #7 is a tail risk.
- Exact Medicare CLFS revenue mix (what % of Dx is Medicare) to size the 2027+ 15%/yr cap exposure — needs 10-K Medicare-revenue disclosure.
- ColoSense / Plasma Detect MRD reimbursement traction (covered lives) — next earnings.
STRENGTHENED.
Primary and supporting material
Sources
10 sources preserved from the latest qualified research update.
- sec.govLabcorp Q2 2026 Form 10 QOpen source ↗
- sec.govLabcorp Q2 2026 earnings release, Exhibit 99.1Open source ↗
- sec.govsec.govOpen source ↗
- sec.govsec.govOpen source ↗
- sec.govsec.govOpen source ↗
- sec.govsec.govOpen source ↗
- sec.govsec.govOpen source ↗
- cms.govcms.govOpen source ↗
- ir.labcorp.comLabcorp investor relationsOpen source ↗
- ir.labcorp.comLabcorp financial reportsOpen source ↗
Historical long-form synthesis
Labcorp (LH): The Last Mile of Healthspan Diagnostics
1,080 words · Research as of 10 Sept 2026
Preserved research context: this long-form synthesis reflects the evidence and valuation snapshot available on 10 Sept 2026. Use the current snapshot above for the latest signal, conviction, target and market-cap values.
# Labcorp Holdings (LH): The Last Mile of Healthspan Measurement
Investment Thesis
Labcorp owns the physical last mile of American diagnostics, the point where a healthspan thesis becomes a blood draw. FY2025 revenue was $13,951.7M across two businesses: Diagnostics Laboratories, roughly 78% of revenue, and Biopharma Laboratory Services, roughly 22%, the legacy Covance central-lab and CRO book. Q2 2026 revenue was $3,731.1M, up 5.8% year over year, with operating income of $451.6M at a 12.1% margin, up 90 basis points, net earnings of $298.7M, and diluted EPS of $3.64, up 28.5%. Management raised FY2026 guidance to revenue of $14,710M to $14,827M, adjusted EPS of $18.10 to $18.55, and free cash flow of $1,240M to $1,360M.
What makes Labcorp more than a mature lab compounder is that it is a last-mile toll-road with a contracted second engine, and both are inflecting at once. Diagnostics price and mix was positive 3.0% in Q2 2026, which is positive pricing in a sector defined by Medicare fee-schedule deflation. And Biopharma Laboratory Services Central Labs grew 9.8% year over year against a record $8.73B backlog.
Our differentiated read is STRENGTHENED, with a toll-road classification of 7, STRONG PROXY, and scores of 6, 6, and 7 across technical scarcity, economic capture, and time to monetize. The ceiling on the thesis is not demand. It is the duopoly.
Healthspan / Value-Chain Relevance
Labcorp is the Maintain layer in physical form: more than 2,200 patient service centers and more than 7,000 in-office phlebotomists, roughly 9,200 collection points, supporting approximately 175 million patient encounters annually, per the FY2025 10-K.
The bottleneck is physical and regulatory in equal measure. You cannot route a blood draw, a biopsy, or a clinical-trial sample through an app. Replicating the collection network at even $1M per leased and fitted patient service center implies a commitment of $2.2B or more in greenfield capital, plus three to five years of payer credentialing and EMR ordering-workflow integration before a new entrant reaches parity.
The second engine is underrated. Biopharma Laboratory Services ended Q2 2026 with $8.73B of backlog against FY2026 BLS revenue guidance of $3,269M to $3,300M, coverage of roughly 2.67x, with 84% of next-year revenue already contracted. A trial sponsor cannot switch central labs mid-study without invalidating assay continuity for an FDA submission; the switching cost is a re-run of the entire clinical data package. That is a stronger form of lock-in than a reference-testing contract, and it is growing faster than the base: Central Labs rose 9.8% while Early Development fell 1.4%.
Finally, the pricing proof. Diagnostics price and mix was positive 3.5% in FY2025 and positive 3.0% in Q2 2026 even as PAMA and CLFS deflate the routine-test basket, because mix is rotating toward oncology and esoteric testing, including ColoSense, Plasma Detect MRD, and companion diagnostics, which carry higher reimbursement. Positive price in a reimbursement-constrained industry is the cleanest available read on genuine pricing power.
Catalysts
- ColoSense, the first FDA-approved RNA-based colorectal-cancer screening test, is launching nationwide with Labcorp as primary distributor, a volume and mix catalyst at once.
- Plasma Detect MRD, through the Fox Chase collaboration, and the VENTANA PTEN companion diagnostic are near-term revenue contributors in esoteric oncology.
- CMS averted the full 2026 PAMA and CLFS fee-schedule cut, removing a near-term reimbursement headwind.
- Capital return: $353.8M of buybacks and $58.7M of dividends in Q2, with $1.4B of buyback authorization remaining.
Positioning / What the Market May Be Missing
The market's Labcorp model is a diagnostics compounder plus a shrinking CRO business, capped by Medicare deflation. Three refinements.
First, the mix is rotating toward reimbursement-favored testing faster than the deflation narrative assumes. Positive price and mix of 3.0% to 3.5% in a market where Medicare's clinical-lab fee schedule is structurally declining means the esoteric and oncology portfolio is already out-earning the routine basket. ColoSense, MRD, and companion diagnostics are not experiments; they are the mix.
Second, Biopharma Laboratory Services is not a legacy drag, it is contracted visibility. At 2.67x backlog coverage and 84% of next-year revenue already booked, BLS functions as a visibility instrument on the broader biopharma research cycle, in a quarter when peer CROs reported flat to single-digit growth. The split between Central Labs at positive 9.8% and Early Development at negative 1.4% shows precisely which part of that book is the toll-road.
Third, the capital allocation is self-reinforcing. Labcorp is deploying roughly $638M in a single quarter across acquisitions, buybacks, and dividends against Q2 net earnings of $298.7M: buying regional outreach labs to consolidate the moat, retiring stock, and still guiding to $1.24B to $1.36B of free cash flow.
The tape has noticed. The packet shows the stock at $321.10, up 17.3% over a year and trading near 14.8x forward earnings, with the $258.28 to $301.33 entry range behind it. This is a WATCH in the research sense, not an entry signal.
Risks and What Invalidates the Thesis
- The Quest Diagnostics duopoly caps pricing power. The bypass test fails the no-substitute bar, because a hospital system can flip outreach testing to Quest with six to twelve months of disruption, so Labcorp cannot price as a sole source.
- PAMA and CLFS secular deflation: 2027 and later per-test Medicare reductions are capped at 15% a year, and cumulative cuts since 2018 have already compressed the routine basket. Averted 2026 cuts are a reprieve, not a reversal.
- China genomics commoditization: BGI and MGI sequencing offered at 30% to 50% discounts threatens the esoteric and genomics niche, which is precisely the growth engine Labcorp is pivoting toward.
- Central-lab CRO is not a monopoly. Biopharma Laboratory Services competes with IQVIA, ICON, and PPD, so the 9.8% Central Labs growth and $8.73B backlog are strong but not sole-source.
- Invalidation: two consecutive years of revenue-per-requisition decline, book-to-bill falling below 1.0x in the biopharma segment, or the loss of a major hospital-channel relationship.
What to Watch Next
- ColoSense reimbursement traction. Covered lives, not approvals, is the number that matters.
- Biopharma backlog conversion: does the $2.75B twelve-month tranche land on schedule, and does book-to-bill hold above 1.0x?
- Medicare exposure in Diagnostics, the key open question for the 2027-and-later fee-schedule caps, which is currently unresolvable from the 10-K.
- Use of the $1.4B remaining buyback authorization versus further network acquisitions.